David Kan

Discovery of <i>N</i>-(2-Chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a Dual Src/Abl Kinase Inhibitor with Potent Antitumor Activity in Preclinical Assays

Louis J. Lombardo, Francis Y. Lee, Ping Chen et al. · Journal of Medicinal Chemistry · 2004 · 1.3K citations · Full text

Medicine, Oncology, Pharmacology +13

Variants of the Antibody Herceptin That Interact with HER2 and VEGF at the Antigen Binding Site

Jenny Boström, Shang‐Fan Yu, David Kan et al. · Science · 2009 · 366 citations

Pharmacy, Molecular Biology, Oncology +17

Antibody targeting of E3 ubiquitin ligases for receptor degradation

Hadir Marei, Wen‐Ting K. Tsai, Yee-Seir Kee et al. · Nature · 2022 · 255 citations · Full text

Life Sciences, Biochemistry, Oncology +16

Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure

Feng Luo, Zheng Yang, Amy Camuso et al. · Clinical Cancer Research · 2006 · 149 citations

Medicine, Pharmacokinetics, Pharmacology +13

Disruption of IRE1α through its kinase domain attenuates multiple myeloma

Adrien Le Thomas, Anna Shemorry, Scot A. Marsters et al. · Proceedings of the National Academy of Sciences · 2019 · 115 citations · Full text

Medicine, Oncology, Pharmacology +17